Agios Pharma (AGIO) Misses Q4 EPS by 15c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St futures jump as Democrats sweep midterms
- CVS Health plans to split into two public companies by 2028
- UBS starts bullish coverage on Ferrari Group on luxury logistics growth
- Citi cuts Adobe rating on ’rising risk of a hard reset’
- Apple shares slip amid guidance for tightening margins, slowing services growth
Tweet
Share
E-mailGet Alerts AGIO Hot Sheet
Join SI Premium – FREE
Agios Pharma (NASDAQ: AGIO) reported Q4 EPS of ($1.81), $0.15 worse than the analyst estimate of ($1.66). Revenue for the quarter came in at $9.8 million versus the consensus estimate of $13.34 million.
For earnings history and earnings-related data on Agios Pharma (AGIO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- McDonald’s posts better-than-expected third-quarter comparable sales
- SelectQuote, Inc. (SLQT) Tops Q1 EPS by 13c ; Offers Guidance
- CS Disco, Inc (LAW) Misses Q3 EPS by 6c; offers guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
